Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits (PGNMID): A Case Series (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1259; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Rituximab-based regimens induced complete remission in 50% of treated patients, while bortezomib-based therapy achieved partial response. Overall, these findings challenge uniform classification as MGRS and emphasize the need for risk-stratified, individualized management. CR, complete remission; PR, partial remission"
Clinical • Acute Kidney Injury • Glomerulonephritis • Lupus Nephritis • Monoclonal Gammopathy • Nephrology • Renal Disease
|
|
Jasmine Nadayil; Anhthu Trinh; Vaishnavi Jayakumar; Claude Bassil; Akram Audi
|